Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Immucor, Inc.
483
•Immucor, Inc.•February 20, 2025

Immucor, Inc. – FDA 483, Feb 20, 2025

Record Details

Immucor, Inc., a medical device manufacturer in Norcross, Georgia, underwent an FDA inspection from February 10 to February 20, 2025. The resulting Form 483 details seven significant observations concerning the facility's quality management and contamination control systems. Investigators identified apparent biological growth on several HEPA filters in production areas, some of which had not been replaced since 2009. This lack of maintenance coincided with thousands of consumer complaints regarding reagent red blood cells, including reports of bacterial contamination and incorrect test results.

Furthermore, the firm failed to establish adequate procedures for Corrective and Preventive Actions (CAPA). Specifically, Immucor did not thoroughly investigate the root causes of microbiological contamination or assess the risk to other product batches. The FDA also noted deficiencies in risk analysis, particularly regarding the use of products on unvalidated testing platforms and the potential for false-negative results that could lead to life-threatening medical errors. Additional issues included inadequate tracking of product rejection rates, failure to follow internal investigation timelines, and missing justifications for not reporting certain field actions to the agency.

These observations were issued under the regulatory framework of the Federal Food, Drug, and Cosmetic Act. While the firm has promised to correct most of these issues and verified the correction of one reporting violation during the inspection, they are required to implement robust quality controls. Necessary actions include updating maintenance schedules, formalizing complaint investigations, and ensuring all potential medical device reports are properly assessed and submitted to regulatory authorities.

Company
Immucor, Inc.
Inspection date
February 20, 2025
Product type
devices
Office
Atlanta District Office
People
  • Cody D. Rickman
  • Emilia A. Sippert (FDA_PERSONNEL)
  • Kimberly M. Bigler (FDA_PERSONNEL)
  • Edward A. Brunt (FDA_PERSONNEL)
View Company Profile

ID · 12d32dcf-a953-491d-a918-68f570e75a81

Other documents for Immucor, Inc.
  • 483 - 2021-07-30July 30, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Immucor, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.